MCID: HMN021
MIFTS: 47

Human T-Cell Leukemia Virus Type 1

Categories: Rare diseases, Immune diseases, Cancer diseases, Skin diseases, Blood diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 50
Human T Lymphotropic Virus Type 1 50
Htlv-1 50

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

NIH Rare Diseases : 50 human t-cell leukemia virus, type 1 (htlv-1) is a retroviral infection that affect the t cells (a type of white blood cell). although this virus generally causes no signs or symptoms, some affected people may later develop adult t-cell leukemia (atl), htlv-1 associated myelopathy/tropical spastic paraparesis (ham/tsp) or other medical conditions. htlv-1 is spread by blood transfusions, sexual contact and sharing needles. it can also be spread from mother to child during birth or breast-feeding. there is no cure or treatment for htlv-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life. last updated: 12/10/2014

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and infective dermatitis associated with htlv-1. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are IL-2 Pathway and G-Beta Gamma Signaling. The drugs Daclizumab and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and brain, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)
id Related Disease Score Top Affiliating Genes
1 htlv-1 associated myelopathy/tropical spastic paraparesis 11.3
2 infective dermatitis associated with htlv-1 11.3
3 leukemia 11.2
4 t-cell leukemia 11.2
5 adult t-cell leukemia 10.5
6 lymphoma 10.4
7 webster deming syndrome 10.3 CRTC1 CRTC3
8 tropical spastic paraparesis 10.2
9 spastic paraparesis 10.2
10 spasticity 10.2
11 hiv-1 10.1
12 constricting bands, congenital 10.1 CREB1 CREBBP EP300
13 parkinsonism with dementia of guadeloupe 10.1 ATF1 CREB1
14 hepatitis c virus 10.0
15 hepatitis 10.0
16 hepatitis c 10.0
17 rheumatoid arthritis 9.9
18 lung cancer 9.9
19 retinoblastoma 9.9
20 arthritis 9.9
21 chronic lymphocytic leukemia 9.9
22 t-cell large granular lymphocyte leukemia 9.9
23 gastric lymphoma 9.9
24 graves' disease 9.9
25 uveitis 9.9
26 arthropathy 9.9
27 borna disease 9.9
28 eye disease 9.9
29 neuronitis 9.9
30 herpes simplex 9.9
31 glioblastoma 9.9
32 large granular lymphocyte leukemia 9.9
33 pituitary tumors 9.9
34 endotheliitis 9.9
35 hunter macpherson syndrome 9.6 CNTN2 CREB1 CREBBP EP300 NFKB1
36 subacute thyroiditis 9.4 CNTN2 CREB1 CRTC2 GLI2 SLC2A1
37 cranioectodermal dysplasia 1 9.1 CDKN1A CREBBP EP300 JUN
38 hunter carpenter macdonald syndrome 4.8 APOBEC3B ATF1 BST2 CDKN1A CNTN2 CREB1

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.96 CREB1 JUN CREBBP NFKB1 SLC2A1 CRTC1
2 endocrine/exocrine gland MP:0005379 9.92 CREB1 JUN CREBBP NFKB1 CRTC1 EP300
3 embryo MP:0005380 9.91 GLI2 CREB1 JUN CREBBP SLC2A1 EP300
4 homeostasis/metabolism MP:0005376 9.9 CREB1 JUN CREBBP NFKB1 CRTC1 SLC2A1
5 muscle MP:0005369 9.5 CREBBP NFKB1 CRTC3 EP300 CDKN1A GLI2
6 respiratory system MP:0005388 9.17 JUN CREBBP NFKB1 EP300 CDKN1A GLI2

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
2 Antibodies Phase 4,Phase 1,Phase 2
3 Immunoglobulins Phase 4,Phase 1,Phase 2
4 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
5
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
6
Zidovudine Approved Phase 2, Phase 3,Phase 1,Early Phase 1 30516-87-1 35370
7
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
9
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
10
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
11
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
12 Anti-HIV Agents Phase 2, Phase 3, Phase 1, Early Phase 1
13 Anti-Infective Agents Phase 2, Phase 3, Phase 1, Early Phase 1
14 Anti-Retroviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
15 Antiviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
16 Anticonvulsants Phase 3,Phase 1,Phase 2
17 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
18 HIV Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
19 Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
20 Raltegravir Potassium Phase 2, Phase 3,Phase 1,Early Phase 1
21 Antimetabolites Phase 2, Phase 3,Phase 1,Early Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
23 Reverse Transcriptase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
24 Antioxidants Phase 3
25 Phosphodiesterase Inhibitors Phase 3
26 Platelet Aggregation Inhibitors Phase 3
27 Protective Agents Phase 3
28 Radiation-Protective Agents Phase 3
29 Vasodilator Agents Phase 3
30 Antifungal Agents Phase 2, Phase 3
31 Antirheumatic Agents Phase 2, Phase 3,Phase 1
32 Calcineurin Inhibitors Phase 2, Phase 3
33 Cyclosporins Phase 2, Phase 3
34 Dermatologic Agents Phase 2, Phase 3
35 Antimanic Agents Phase 3,Phase 1,Phase 2
36 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
37 GABA Agents Phase 3,Phase 1,Phase 2
38 Psychotropic Drugs Phase 3,Phase 1,Phase 2
39 Tranquilizing Agents Phase 3,Phase 1,Phase 2
40 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
42 HIV Protease Inhibitors Phase 2, Phase 3
43
protease inhibitors Phase 2, Phase 3
44
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
45
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
46
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
47
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
48
Lenograstim Approved Phase 2 135968-09-1
49
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
50
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 57)

id Name Status NCT ID Phase Drugs
1 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
4 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine
5 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
6 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00773292 Phase 2, Phase 3 ciclosporin
7 Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM) Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
8 A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) Recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
9 Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Recruiting NCT01854762 Phase 2, Phase 3 Raltegravir;Lopinavir/Ritonavir
10 Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Unknown status NCT01620736 Phase 2 Raltegravir
11 Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
12 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
13 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
14 Anti-Tac for Treatment of Leukemia Completed NCT00001941 Phase 1, Phase 2
15 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
16 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
17 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
18 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
19 Ruxolitinib for Adult T-Cell Leukemia Recruiting NCT01712659 Phase 2 Ruxolitinib
20 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Recruiting NCT02631746 Phase 2
21 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
22 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
23 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
24 Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 1, Phase 2 Valproic Acid;Zidovudine
25 The HAM Infliximab Study Terminated NCT00823641 Phase 2 Infliximab
26 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
27 Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00076843 Phase 1 Hu MiK-Beta-1
28 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Completed NCT01169298 Phase 1 Lenalidomide
29 Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM) Recruiting NCT02961712 Phase 1
30 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
31 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Unknown status NCT01754311
32 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
33 Notification of Donors With Positive Microbiology Markers Unknown status NCT01050881
34 Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica Completed NCT00339807
35 MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis Completed NCT00034723
36 A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis Completed NCT00340821
37 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa Completed NCT02439918
38 Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 Completed NCT00339638
39 Dual Algorithm Post Market Clinical Study Completed NCT03146013
40 Neuroimmunology Branch Repository Completed NCT01581567
41 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
42 Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
43 Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia Completed NCT01520246
44 Late Effects of Treatment for Sarcomas in Children Completed NCT00006515
45 Retrovirus Epidemiology Donor Study-II (REDS-II) Completed NCT00097006
46 Evaluation of Patients With HAM/TSP Recruiting NCT00001778
47 Raltegravir for HAM/TSP Recruiting NCT01867320 Early Phase 1 Raltegravir
48 Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus Recruiting NCT02877030
49 Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Recruiting NCT00001582
50 Idiopathic CD4 Lymphocytopenia Recruiting NCT02113930

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

39
T Cells, Breast, Brain, Nk Cells, Liver, Monocytes, B Cells

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 448)
id Title Authors Year
1
Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results. ( 28701419 )
2017
2
RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells. ( 28478312 )
2017
3
Failure to prevent human T-cell leukemia virus type 1 mother-to-child transmission in Japan. ( 28211219 )
2017
4
Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging. ( 28753950 )
2017
5
Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line. ( 28615198 )
2017
6
Effects of expressing human T-cell leukemia virus type 1 (HTLV-I) oncoprotein Tax on DOK1, DOK2 and DOK3 gene expression in mice. ( 28302940 )
2017
7
Human T Cell Leukemia Virus Type 1 and Eye Diseases. ( 28263674 )
2017
8
Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. ( 26819304 )
2016
9
Enhanced Stabilization of MCL1 by the Human T-Cell Leukemia Virus Type 1 bZIP Factor Is Modulated by Blocking the Recruitment of Cullin 1 to the SCF Complex. ( 27697867 )
2016
10
Induction of Cell Death in Growing Human T-Cells and Cell Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1 Tax. ( 26829041 )
2016
11
Permissive Sense and Antisense Transcription from the 5' and 3' Long Terminal Repeats of Human T-Cell Leukemia Virus Type 1. ( 26792732 )
2016
12
Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. ( 26996829 )
2016
13
Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. ( 27677902 )
2016
14
The Tax-Inducible Actin-Bundling Protein Fascin Is Crucial for Release and Cell-to-Cell Transmission of Human T-Cell Leukemia Virus Type 1 (HTLV-1). ( 27776189 )
2016
15
Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel cis-Acting Regulatory Sequence. ( 26581997 )
2016
16
Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB. ( 26739459 )
2016
17
Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation. ( 26819312 )
2016
18
Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence. ( 26198240 )
2015
19
Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. ( 26608313 )
2015
20
Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study. ( 26292315 )
2015
21
Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. ( 25473052 )
2015
22
SIRT1 Suppresses Human T-Cell Leukemia Virus Type 1 Transcription. ( 26063426 )
2015
23
Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. ( 26174324 )
2015
24
Human T-cell leukemia virus type 1 Tax oncoprotein represses the expression of the BCL11B tumor suppressor in T-cells. ( 25613934 )
2015
25
Advanced human T-cell leukemia virus type 1 carriersA and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. ( 25703103 )
2015
26
Viral Source-Independent High Susceptibility of Dendritic Cells to Human T-Cell Leukemia Virus Type 1 Infection Compared to That of T Lymphocytes. ( 26269171 )
2015
27
Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. ( 26324707 )
2015
28
Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. ( 25883717 )
2015
29
Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease. ( 25889320 )
2015
30
Regulation of the tumor marker Fascin by the viral oncoprotein Tax of human T-cell leukemia virus type 1 (HTLV-1) depends on promoter activation and on a promoter-independent mechanism. ( 26363219 )
2015
31
Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-I_B inhibitor A20 and constitutive NF-I_B signaling. ( 25774694 )
2015
32
miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. ( 25568327 )
2015
33
Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission. ( 24284316 )
2014
34
Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis. ( 24352466 )
2014
35
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. ( 24403582 )
2014
36
Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. ( 24792037 )
2014
37
Reevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors. ( 25363675 )
2014
38
Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. ( 23606621 )
2013
39
Molecular study of HBZ and gp21 human T cell leukemia virus type 1 proteins isolated from different clinical profile infected individuals. ( 23800288 )
2013
40
Failure in activation of the canonical NF-I_B pathway by human T-cell leukemia virus type 1 Tax in non-hematopoietic cell lines. ( 23791017 )
2013
41
Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1. ( 23888327 )
2013
42
LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription. ( 23577667 )
2013
43
Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats. ( 23622267 )
2013
44
Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. ( 24060211 )
2013
45
Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. ( 24139400 )
2013
46
An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. ( 23750452 )
2013
47
Human T-cell leukemia virus type 1 Tax protein interacts with and mislocalizes the PDZ domain protein MAGI-1. ( 23279616 )
2013
48
Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1. ( 23033806 )
2013
49
HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-I_B activation and HTLV-1 replication. ( 24109220 )
2013
50
The four and a half LIM family members are novel interactants of the human T-cell leukemia virus type 1 Tax oncoprotein. ( 23616667 )
2013

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 ATF1 CREB1 CREBBP EP300 JUN NFKB1
2
Show member pathways
12.9 CREB1 CREBBP EP300 GLI2 JUN NFKB1
3
Show member pathways
12.88 CREB1 CREBBP EP300 JUN NFKB1
4
Show member pathways
12.86 CREB1 CREBBP CRTC1 CRTC2 CRTC3
5
Show member pathways
12.82 CREBBP EP300 JUN NFKB1 XPO1
6
Show member pathways
12.82 CREB1 CREBBP EP300 JUN NFKB1 SLC2A1
7
Show member pathways
12.81 ATF1 CDKN1A CREB1 JUN NFKB1
8 12.7 CDKN1A CREB1 CREBBP CRTC2 EP300 NFKB1
9
Show member pathways
12.66 CREB1 CREBBP JUN NFKB1
10 12.65 CDKN1A CREBBP EP300 GLI2 JUN NFKB1
11
Show member pathways
12.6 CDKN1A CREBBP EP300 NFKB1
12
Show member pathways
12.57 CDKN1A CREB1 CREBBP EP300 JUN NFKB1
13
Show member pathways
12.54 ATF1 CREB1 JUN NFKB1
14 12.53 CDKN1A CREBBP EP300 NFKB1
15 12.52 CRTC1 CRTC2 CRTC3 SLC2A1
16
Show member pathways
12.5 CREB1 CREBBP EP300 JUN NFKB1
17
Show member pathways
12.42 CDKN1A CREB1 EP300 NFKB1
18
Show member pathways
12.38 CDKN1A CREB1 CREBBP EP300 GLI2
20
Show member pathways
12.32 CREB1 CREBBP EP300 JUN NFKB1
21
Show member pathways
12.29 ATF1 EP300 JUN NFKB1
22 12.27 CREB1 CREBBP EP300 NFKB1
23 12.26 CDKN1A CREBBP EP300 JUN NFKB1 XPO1
24
Show member pathways
12.25 CDKN1A JUN NFKB1 XPO1
25 12.24 CDKN1A CREB1 CREBBP EP300 JUN NFKB1
26 12.21 CREB1 CREBBP EP300 JUN NFKB1
27
Show member pathways
12.17 CDKN1A EP300 JUN NFKB1
28
Show member pathways
12.17 CREB1 CREBBP JUN NFKB1
29 12.16 ATF1 CREB1 EP300 JUN NFKB1
30 12.14 CREB1 CRTC1 JUN NFKB1
31
Show member pathways
12.13 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
32 12.1 CDKN1A CREBBP EP300 JUN
33 12.09 CDKN1A CREBBP EP300 JUN
34
Show member pathways
12.09 CREB1 CREBBP CRTC1 CRTC2 CRTC3
35
Show member pathways
12.05 CREBBP GLI2 XPO1
36 12.05 CREB1 JUN NFKB1
37
Show member pathways
12.04 CREBBP EP300 JUN
38
Show member pathways
12.03 CREB1 JUN NFKB1
39
Show member pathways
12.03 ATF1 JUN NFKB1
40
Show member pathways
12 CREB1 JUN NFKB1
41 12 CREBBP EP300 SLC2A1
42 11.99 CDKN1A JUN NFKB1
43
Show member pathways
11.99 CREB1 CRTC2 NFKB1 SLC2A1
44 11.96 CREB1 JUN NFKB1
45 11.95 CREB1 CREBBP CRTC2 EP300 SLC2A1
46 11.94 ATF1 CREB1 JUN NFKB1
47 11.93 ATF1 CREB1 JUN
48 11.92 CDKN1A CREBBP EP300 NFKB1 SLC2A1
49
Show member pathways
11.91 ATF1 CREB1 JUN
50
Show member pathways
11.89 CDKN1A CREBBP EP300

GO Terms for Human T-Cell Leukemia Virus Type 1

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.97 APOBEC3B ATF1 CDKN1A CREB1 CREBBP CRTC1
2 nucleoplasm GO:0005654 9.4 ATF1 CDKN1A CREB1 CREBBP CRTC1 CRTC2
3 histone acetyltransferase complex GO:0000123 9.26 CREBBP EP300
4 transcription factor complex GO:0005667 9.26 ATF1 CREB1 EP300 JUN

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 transcription, DNA-templated GO:0006351 9.96 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 CREB1 CREBBP EP300 GLI2 JUN NFKB1
3 response to drug GO:0042493 9.89 CDKN1A CREB1 JUN XPO1
4 transcription from RNA polymerase II promoter GO:0006366 9.88 ATF1 CREB1 EP300 GLI2 JUN NFKB1
5 response to organic cyclic compound GO:0014070 9.79 ATF1 CDKN1A JUN
6 regulation of cell cycle GO:0051726 9.78 CDKN1A EP300 JUN
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 CREBBP EP300 NFKB1
8 response to organic substance GO:0010033 9.72 CDKN1A CREB1 JUN
9 circadian rhythm GO:0007623 9.71 CREB1 EP300 JUN
10 protein homotetramerization GO:0051289 9.69 CRTC1 CRTC2 CRTC3
11 positive regulation of type I interferon production GO:0032481 9.67 CREBBP EP300 NFKB1
12 rhythmic process GO:0048511 9.67 CREB1 CREBBP CRTC1 EP300
13 positive regulation of DNA replication GO:0045740 9.65 ATF1 GLI2 JUN
14 energy homeostasis GO:0097009 9.58 CRTC1 CRTC3
15 response to muscle stretch GO:0035994 9.58 JUN NFKB1
16 positive regulation of long-term synaptic potentiation GO:1900273 9.57 CREB1 CRTC1
17 positive regulation by host of viral transcription GO:0043923 9.56 EP300 JUN
18 protein acetylation GO:0006473 9.52 CREBBP EP300
19 viral process GO:0016032 9.5 CREB1 CREBBP CRTC1 CRTC2 CRTC3 EP300
20 N-terminal peptidyl-lysine acetylation GO:0018076 9.46 CREBBP EP300
21 positive regulation of CREB transcription factor activity GO:0032793 9.33 CRTC1 CRTC2 CRTC3
22 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.32 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3
23 regulation of transcription, DNA-templated GO:0006355 10.02 ATF1 CREB1 CREBBP CRTC1 CRTC2 CRTC3

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.99 ATF1 CREB1 CREBBP GLI2 JUN NFKB1
2 sequence-specific DNA binding GO:0043565 9.88 ATF1 CREB1 GLI2 JUN NFKB1
3 transcription regulatory region DNA binding GO:0044212 9.73 CREB1 GLI2 JUN NFKB1
4 chromatin binding GO:0003682 9.73 CREBBP CRTC2 EP300 GLI2 JUN NFKB1
5 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.63 CREB1 JUN NFKB1
6 transcription factor binding GO:0008134 9.63 CREB1 CREBBP EP300 GLI2 JUN NFKB1
7 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.58 ATF1 CREB1 JUN
8 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.55 CREB1 JUN
9 regulatory region DNA binding GO:0000975 9.54 CREB1 NFKB1
10 transcription cofactor activity GO:0003712 9.54 CREB1 CREBBP EP300
11 acetyltransferase activity GO:0016407 9.52 CREBBP EP300
12 cAMP response element binding GO:0035497 9.49 CREB1 JUN
13 peptide N-acetyltransferase activity GO:0034212 9.32 CREBBP EP300
14 cAMP response element binding protein binding GO:0008140 9.13 CRTC1 CRTC2 CRTC3
15 RNA polymerase II activating transcription factor binding GO:0001102 8.92 CREB1 CREBBP EP300 JUN

Sources for Human T-Cell Leukemia Virus Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....